Caris Life Sciences (NASDAQ:CAI) Price Target Raised to $28.00

Caris Life Sciences (NASDAQ:CAI) had its price target upped by Robert W. Baird from $26.00 to $28.00 in a report issued on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

CAI has been the topic of several other research reports. Wall Street Zen downgraded Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Canaccord Genuity Group boosted their price target on Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, December 22nd. Finally, Evercore set a $38.00 price objective on Caris Life Sciences in a research note on Monday, January 5th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $33.50.

Caris Life Sciences Trading Up 4.7%

Shares of Caris Life Sciences stock opened at $20.14 on Friday. The company has a market cap of $5.68 billion and a price-to-earnings ratio of -43.78. The company has a quick ratio of 9.36, a current ratio of 9.93 and a debt-to-equity ratio of 0.79. The firm’s 50 day moving average is $24.42. Caris Life Sciences has a 1 year low of $17.15 and a 1 year high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last issued its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. The business’s quarterly revenue was up 125.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.73) EPS.

Insider Activity at Caris Life Sciences

In other Caris Life Sciences news, insider Luke Thomas Power sold 62,250 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $26.58, for a total value of $1,654,605.00. Following the sale, the insider owned 99,571 shares in the company, valued at approximately $2,646,597.18. The trade was a 38.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Caris Life Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in CAI. Global Retirement Partners LLC boosted its holdings in Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after acquiring an additional 999 shares during the last quarter. Olistico Wealth LLC acquired a new position in shares of Caris Life Sciences in the 4th quarter worth approximately $31,000. MetLife Investment Management LLC boosted its stake in shares of Caris Life Sciences by 84.0% in the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after purchasing an additional 755 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Caris Life Sciences in the 4th quarter valued at $67,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Caris Life Sciences during the fourth quarter worth $81,000.

More Caris Life Sciences News

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 beat and strong revenue growth — CAI reported GAAP EPS of $0.28 (well above estimates) and Q4 revenue of ~$293M, up ~125% YoY, demonstrating accelerating top‑line momentum. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Major interim Achieve 1 readout — The company announced interim data showing Caris Detect (WGS + AI) had superior sensitivity and specificity vs. methylation‑based approaches, a milestone for its MCED launch and long‑term growth potential in early cancer detection. Caris Life Sciences Completes Interim Readout of Achieve 1 Study
• Positive Sentiment: 2026 revenue guidance reaffirmed/raised — Management guided full‑year 2026 revenue to roughly $1.0B–$1.02B (above consensus), supporting sustained growth expectations as profiling services and new product launches scale. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Analyst support — Robert W. Baird initiated coverage / raised its price target (to $28 with an Outperform stance), bringing new institutional attention that can boost demand for the stock. Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
• Positive Sentiment: Product enhancement — Caris added an AI‑powered breast cancer signature to its Caris Molecular Tumor Board Report, expanding clinical utility and potential revenue per case in precision oncology. Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report
• Neutral Sentiment: Mixed analyst moves — BTIG lowered its price target from $45 to $38 but maintained a Buy rating; still bullish but the cut tempers some upside expectations. BTIG price target note
• Neutral Sentiment: Further reading / call details — The Q4 earnings call transcript and additional materials are available for investors who want management commentary on Caris Detect commercialization timing and margin cadence. Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call Transcript

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.